Most Active
OmniAb Signs Eli Lilly Ion Channel Deal Worth Up to $370M, Raises 2026 Cash Guidance
OmniAb, Inc. $OABI
$3.82+13.02%as of publication
- 5D Change
- +12.68%
- Notional
- $69.10M
OmniAb struck a global collaboration and license agreement with Eli Lilly for a new ion channel drug discovery program, with OmniAb eligible to receive an upfront payment plus up to $370 million in research, development and commercial milestones. The deal leverages OmniAb's technology platform and expertise in ion channel discovery and screening. Following the agreement, OmniAb raised its full-year 2026 cash guidance to $49 million-$53 million, up from a prior outlook of $37 million-$41 million.
Shares surged roughly 19% in premarket trading on the news.
© AI-generated summary is provided by Market Flux
Sources
- businesswire.comOmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
- Wallstengine$OABI SIGNS LILLY DEAL WORTH UP TO $370M OmniAb entered a global collaboration and licensing agreement with Eli Lilly for a new ion channel drug discovery program. OmniAb will receive an upfront payment and is eligible for up to $370M in research, development and commercial
- OpenOutcrier$OABI (+19.2% pre) OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with $LLY Eli Lilly & Company
- Marketwirenews$OABI - OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly Company OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therape…